Normalized ctTHb levels measured prior to neoadjuvant chemotherapy can predict breast cancer response to NAC and potentially be used to improve personalized therapeutic strategies for HER-2 positive tumors.
© 2020 The Author(s)
You do not have subscription access to this journal. Citation lists with outbound citation links are available to subscribers only. You may subscribe either as an OSA member, or as an authorized user of your institution.
Contact your librarian or system administrator
Login to access OSA Member Subscription